Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 501–600 of 1,056
Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
Rudland, P. S., Platt-Higgins, A. M., El‐Tanani, M., Rudland, S. D. S., Barraclough, R., Winstanley, J. H. R., Howitt, R., & West, C. R. (2002) · PubMed · Cited by 276
Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker?
Hashimoto, Y., Skacel, M., & Adams, J. C. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.05.004 · Cited by 275
Bueno-de-Mesquita, J. M., van Harten, W. H., Retel, V. P., van 't Veer, L. J., van Dam, F. S., Karsenberg, K., Douma, K. F., van Tinteren, H., Peterse, J. L., Wesseling, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70346-7 · Cited by 274
Real-Time PCR Technology for Cancer Diagnostics
Bernard, P. S., & Wittwer, C. T. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1178 · Cited by 273
Treatment of HER2-positive breast cancer
Figueroa-Magalhães, M. C., Jelovac, D., Connolly, R. M., & Wolff, A. C. (2014) · The Breast · doi:10.1016/j.breast.2013.11.011 · Cited by 273
“The HER2-positive phenotype observed in about 15% of patients is of great scientific interest as HER2 overexpression is associated with worse clinical outcome (worse prognosis) in the absence of therapy [2].”
BackgroundTzahar, E., Levkowitz, G., Karunagaran, D., Yi, L., Peles, E., Lavi, S., Chang, D., Liu, N., Yayon, A., & Wen, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31521-1 · Cited by 272
Fabian, C. J., Kimler, B. F., Zalles, C. M., Klemp, J. R., Kamel, S., Zeiger, S., & Mayo, M. S. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1217 · Cited by 272
Involvement of pp60c-src with two major signaling pathways in human breast cancer.
Luttrell, D. K., Lee, A., Lansing, T. J., Crosby, R. M., Jung, K. D., Willard, D., Luther, M., Rodriguez, M., Berman, J., & Gilmer, T. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.83 · Cited by 271
Pegram, M. D., Pienkowski, T., Northfelt, D. W., Eiermann, W., Patel, R., Fumoleau, P., Quan, E., Crown, J., Toppmeyer, D., Smylie, M., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh133 · Cited by 271
Self-citationSteroid receptors and other prognostic factors in primary breast cancer.
Clark, G. M., & McGuire, W. L. (1988) · PubMed · Cited by 271
Self-citationVERBEEK, B. S., VROOM, T. M., ADRIAANSEN-SLOT, S. S., OTTENHOFF-KALFF, A. E., GEERTZEMA, J. G. N., HENNIPMAN, A., & RIJKSEN, G. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199612)180:4<383::aid-path686>3.0.co;2-n · Cited by 270
Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?
Sawyer, D. B., Peng, X., Chen, B., Pentassuglia, L., & Lim, C. C. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.06.007 · Cited by 270
“ErbB2 is overexpressed in 25-30% of human breast cancer and this is associated with enhanced tumor aggressiveness and a high risk of relapse and death [61].”
BackgroundTransformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo
Zhang, L., Jing, D., Jiang, N., Rojalin, T., Baehr, C. M., Zhang, D., Xiao, W., Wu, Y., Cong, Z., Li, J. J., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-019-0626-4 · Cited by 270
Targeting HER proteins in cancer therapy and the role of the non-target HER3
Hsieh, A. C., & Moasser, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603910 · Cited by 269
“The human epidermal growth factor receptor (HER) family of proteins consisting of EGFR, HER2, HER3, and HER4 are type I transmembrane growth factor receptors that activate intracellular signalling pathways in response to extracellular signals.”
BackgroundInsights from transgenic mouse models of ERBB2-induced breast cancer
Ursini-Siegel, J., Schade, B., Cardiff, R. D., & Muller, W. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2127 · Cited by 269
“gov/cancertopics/types/breast/">breast cancer , which correlates with poor patient outcom”
BackgroundSensitization of breast cancer cells to radiation by trastuzumab.
Liang, K., Lü, Y., Jin, W., Ang, K. K., Milas, L., & Fan, Z. (2003) · PubMed · Cited by 269
Mauriac, L., Durand, M., Avril, A., & Dilhuydy, J.-M. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057953 · Cited by 268
Schuuring, E. (1995) · Gene · doi:10.1016/0378-1119(94)00562-7 · Cited by 268
HER2 as a Prognostic Factor in Breast Cancer
Ménard, S., Fortis, S., Castiglioni, F., Agresti, R., & Balsari, A. (2001) · Oncology · doi:10.1159/000055404 · Cited by 268
“…gene amplification/protein overexpression has been detected in 20 to 30% of human breast carcinomas and studies have indicated that HER2 amplification/ overexpression plays a role in malignant transformation and tumorigenesis [Di Fiore et al. 1987; Hudziak et al. 1987; Slamon et al. 1987, 1989].”
BackgroundOverexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
Berchuck, A., Rodriguez, G., Kinney, R. B., Soper, J. T., Dodge, R. K., Clarke‐Pearson, D. L., & Bast, R. C. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90615-x · Cited by 268
Nahta, R., Yuan, L. X. H., Du, Y., & Esteva, F. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0423 · Cited by 267
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., & de Azambuja, E. (2021) · Cancers · doi:10.3390/cancers13112824 · Cited by 267
Dowsett, M., & Dunbier, A. K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0974 · Cited by 267
Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis
Fang, F., Turcan, S., Rimner, A., Kaufman, A., Giri, D., Morris, L. G. T., Shen, R., Seshan, V., Mo, Q., Heguy, A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001875 · Cited by 267
Rayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265
“Another group studying neuroblastoma cells documented that loss of p53, including loss by MDM2- induced degradation, resulted in high-level drug resistance to melphalan (L-PAM) [91]. cancers, where HER-2 is overexpressed in an estimated 30% of tumors [97].”
BackgroundBasso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
“Ampli®cation and overexpression of the HER2 gene occurs in 30% of breast tumors and a signi®cant number of other cancers (Slamon et al., 1987, 1989; Tal et al., 1988).”
BackgroundPianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J., & Sonenshein, G. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204257 · Cited by 265
Mechanism of action of anti-HER2 monoclonal antibodies
Baselga, J., & Albanell, J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s35 · Cited by 265
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
Idowu, M. O., Kmieciak, M., Dumur, C., Burton, R. S., Grimes, M. M., Powers, C. N., & Manjili, M. H. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.05.005 · Cited by 264
Current Perspectives on HER2 Testing: A Review of National Testing Guidelines
Bilous, M., Dowsett, M., Hanna, W., Isola, J., Lebeau, A., Moreno, A., Penault-Llorca, F., Rüschoff, J., Tomasic, G., & van de Vijver, M. (2003) · Modern Pathology · doi:10.1097/01.mp.0000052102.90815.82 · Cited by 264
“The subset of patients with breast cancer demonstrating a HER2-positive status has aggressive tumors and a poor prognosis (”
BackgroundNew Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
Anido, J., Matar, P., Albanell, J., Guzmán, M., Rojo, F., Arribas, J., Averbuch, S. D., & Baselga, J. M. (2003) · PubMed · Cited by 264
Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung.
WEINER, D. B., Nordberg, J. E., Robinson, R. A., Nowell̀, P. C., Gazdar, A. F., Greene, M. I., Williams, W. V., Cohen, J. A., & Kern, J. A. (1990) · PubMed · Cited by 264
Menendez, J. A., Vellon, L., Colomer, R., & Lupu, R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi090 · Cited by 263
Molecular mechanisms of curcumin action: Gene expression
Shishodia, S. (2013) · BioFactors · doi:10.1002/biof.1041 · Cited by 263
“Almost 30% of the breast cancer cases have been shown to overexpress the HER2/neu protooncogene that play an important role in the pathogenesis and progression of aggressive breast cancers [117].”
BackgroundGianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P.-L., Cameron, D. A., Miles, D., Salvagni, S., Wardley, A., Goeminne, J.-C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1661 · Cited by 262
“Receptor heterodimerization may have a critical role in breast cancers that overexpress multiple members of the HER family.(7-11) Furthermore, dysregulation of HER signaling, including ligand overexpression or abnormal activity, decreased receptor turnover, or receptor mutation can also increase HER signaling activity…”
BackgroundErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner
Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., & Hynes, N. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5042 · Cited by 262
Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I. E., Vogel, C. L., Burris III, H. A., LoRusso, P. M., Yi, J.-H., Saad, O., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1817-3 · Cited by 262
Prognostic Genes of Breast Cancer Identified by Gene Co-expression Network Analysis
Tang, J., Kong, D., Cui, Q., Wang, K., Zhang, D., Gong, Y., & Wu, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00374 · Cited by 262
“HER2 expression was found to be upregulated in over 30% patients with breast cancer (10).”
BackgroundHicks, D. G., Short, S. M., Prescott, N. L., Tarr, S. M., Coleman, K. A., Yoder, B. J., Crowe, J. P., Choueiri, T. K., Dawson, A. E., Budd, G. T., et al. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213306.05811.b9 · Cited by 262
Molecular classification of breast cancer
Vuong, D., Simpson, P. T., Green, B., Cummings, M. C., & Lakhani, S. R. (2014) · Virchows Archiv · doi:10.1007/s00428-014-1593-7 · Cited by 262
“HER2 positivity is seen in 13–20 % of invasive breast cancers, and more than half of these tumours are hormone receptor-negative [22, 23].”
BackgroundBenson, J. R., Jatoi, I., Keisch, M., Esteva, F. J., Makris, A., & Jordan, V. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60316-0 · Cited by 261
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Kreutzfeldt, J., Rozeboom, B. J., Dey, N., & De, P. K. (2020) · PubMed · Cited by 261
Tan, M., Yao, J., & Yu, D. (1997) · PubMed · Cited by 261
Ross, J. S., & Fletcher, J. A. (1998) · The Oncologist · doi:10.1634/theoncologist.3-4-237 · Cited by 260
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
Pegram, M. D., Pauletti, G., & Slamon, D. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006111117877 · Cited by 259
Self-citationRilke, F., Colnaghi, M. I., Cascinelli, N., Andreola, S., Baldini, M. T., Bufalino, R., Porta, G. D., Ménard, S., Pierotti, M. A., & Testori, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490109 · Cited by 259
Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0962 · Cited by 259
Xia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258
“…literature has established ErbB2 as a key mediator of tumor cell growth and survival, predicting a poor clinical outcome in the 25 – 30% of breast cancer patients whose tumors overexpress ErbB2 or demonstrate ErbB2 gene amplification (Slamon et al., 1987; Gullick et al., 1991; Bacus et al., 1994).”
BackgroundMechanism of action of trastuzumab and scientific update
BASELGA, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90276-3 · Cited by 258
Jiménez, R. E., Hussain, M., Bianco, F. J., Vaishampayan, U. N., Tabazcka, P., Sakr, W., Pontes, J. E., Wood, D. P., & Grignon, D. J. (2001) · PubMed · Cited by 258
Osborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257
Valero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., von Minckwitz, G., Roche, H., Martin, M., Crown, J., Mackey, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6450 · Cited by 255
“Tumors in which HER2 is amplified are associated with distinct clinical characteristics, including relative resistance to hormonal therapy, a high incidence of relapse, and short disease-free survival and overall survival (OS).(2-11) Trastuzumab is a monoclonal antibody directed against the external domain of the HER2…”
BackgroundSelf-citationReal-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications
Bièche, I., Onody, P., Laurendeau, I., Olivi, M., Vidaud, D., Lidereau, R., & Vidaud, M. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.8.1148 · Cited by 254
The int-2 gene product acts as an epithelial growth factor in transgenic mice.
Muller, W. J., Lee, F. S., Dickson, C., Peters, G., Pattengale, P., & Leder, P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08188.x · Cited by 254
Ravdin, P. M., & Chamness, G. C. (1995) · Gene · doi:10.1016/0378-1119(94)00866-q · Cited by 254
Xia, W., Liu, L.-H., Ho, P., & Spector, N. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207166 · Cited by 253
“In addition, aberrant activation of ErbB2 in breast and other adenocarcinomas predicts for a poor clinical outcome (Slamon et al., 1987, 1989; Gullick et al., 1991; Bacus et al., 1994).”
BackgroundPIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells
Ryo, A., Liou, Y.-C., Wulf, G., Nakamura, M., Lee, S. W., & Lu, K. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5281-5295.2002 · Cited by 253
“Various studies have revealed that Neu or Ras signaling is deregulated in many breast cancers, although mutations and amplifications of these genes were rarely observed (3, 19, 50, 54).”
BackgroundKnutson, K. L., Schiffman, K., Cheever, M. A., & Disis, M. L. (2002) · PubMed · Cited by 253
Receptor tyrosine kinases as targets for anticancer drugs
Zwick, E., Bange, J., & Ullrich, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02217-1 · Cited by 252
Self-citationFilho, O. M., Viale, G., Stein, S., Trippa, L., Yardley, D. A., Mayer, I. A., Abramson, V. G., Arteaga, C. L., Spring, L. M., Waks, A. G., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1557 · Cited by 252
“Historically, amplification of ERBB2 (encoding HER2) defined a subset of breast cancers with aggressive clinical features and poor outcomes (2, 3).”
BackgroundMethodTargeting HER1/EGFR: A molecular approach to cancer therapy
Arteaga, C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00185-4 · Cited by 251
Chu, I., Blackwell, K., Chen, S., & Slingerland, J. (2005) · Cancer Research · doi:10.1158/0008-5472.18.65.1 · Cited by 251
A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters
Demircioğlu, D., Cukuroglu, E., Kindermans, M., Nandi, T., Calabrese, C., Fonseca, N. A., Kahles, A., Lehmann, K.-V., Stegle, O., Brazma, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.018 · Cited by 250
Nordstrom, J. L., Gorlatov, S., Zhang, W., Yang, Y., Huang, L., Burke, S., Li, H., Ciccarone, V., Zhang, T., Stavenhagen, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3069 · Cited by 250
“Introduction HER2, an overexpressed cell-surface oncoprotein that contributes to breast, gastric, and other cancers [1], is a validated therapeutic target, as evidenced by clinical success of the monoclonal antibody (mAb) trastuzumab [2-5].”
BackgroundThe influence of heregulins on human Schwann cell proliferation
Levi, A., Bunge, R., Lofgren, J., Meima, L., Hefti, F., Nikolics, K., & Sliwkowski, M. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-02-01329.1995 · Cited by 250
“…and/or overexpression of erbB2 has been detected in a variety of human malignancies and is found frequently in human mammary carcinomas (Slamon et al., 1987) and breast tumor-derived cell lines (Lewis et al., 1993). rHRG 61 ,77.244 has been shown to bind to human breast cancer cells…”
BackgroundInfluentialTsimberidou, A.-M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2861-1 · Cited by 249
“In breast cancer, amplification and overexpression of the HER2 oncogene is a poor prognostic factor [80].”
Stein, D., Wu, J., Fuqua, S. A., Roonprapunt, C., Yajnik, V., D'Eustachio, P., Moskow, J. J., Buchberg, A. M., Osborne, C. K., & Margolis, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06386.x · Cited by 249
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells
Singh, J. K., Simões, B. M., Howell, S. J., Farnie, G., & Clarke, R. B. (2013) · Breast Cancer Research · doi:10.1186/bcr3436 · Cited by 249
“IL-8 infl ammatory feedback loop in breast cancer: the role of HER2 Up to 25% of breast cancers overexpress HER2, conferring a higher rate of recurrence and mortality [81].”
BackgroundCortés, J., Fumoleau, P., Bianchi, G. V., Petrella, T. M., Gelmon, K., Pivot, X., Verma, S., Albanell, J., Conte, P., Lluch, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 249
Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12–21.32
Popescu, N. C., King, C. R., & Kraus, M. H. (1989) · Genomics · doi:10.1016/0888-7543(89)90343-1 · Cited by 249
Cancer therapy with antibodies
Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00690-x · Cited by 248
Developments in therapy with monoclonal antibodies and related proteins
Shepard, H. M., Phillips, G. L., Thanos, C. D., & Feldmann, M. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-220 · Cited by 248
Targeting Src in breast cancer
Finn, R. S. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn291 · Cited by 248
“Similarly, women with human epidermal growth factor receptor 2 (HER2)-amplified disease have a more aggressive phenotype but are candidates for trastuzumab, which has changed the natural history of this type of breast cancer [2, 3].”
BackgroundPrognostic molecular markers in early breast cancer
Esteva, F. J., & Hortobagyi, G. N. (2004) · Breast Cancer Research · doi:10.1186/bcr777 · Cited by 247
“The HER-2 protein is overexpressed in 60% of ductal carcinomas in situ and in 20–30% of infiltrating breast carcinomas [31,32].”
BackgroundHarris, J. R., Lippman, M. E., Veronesi, U., & Willett, W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208133270706 · Cited by 247
Mechanisms of multistep carcinogenesis and carcinogen risk assessment.
Barrett, J. C. (1993) · Environmental Health Perspectives · doi:10.1289/ehp.931009 · Cited by 246
Tlsty, T. D., Margolin, B. H., & Lum, K. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9441 · Cited by 246
Role of HER receptors family in development and differentiation
Casalini, P., Iorio, M. V., Galmozzi, E., & Ménard, S. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20007 · Cited by 246
“HER-2overexpression,occurring in25–30%ofhuman breast cancers, is associated to shorter time to relapse and lower overall survival (Slamon et al., 1987; Ménard et al., 1996, 1999, 2002).”
BackgroundDysregulated Expression of Adamalysin-Thrombospondin Genes in Human Breast Carcinoma
Porter, S., Scott, S. D., Sassoon, E. M., Williams, M. R., Jones, J. L., Girling, A. C., Ball, R. Y., & Edwards, D. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0398-3 · Cited by 246
“None of the ADAMTS genes showed coexpression with cerbB-2, which was overexpressed in 22% of carcinoma samples, consistent with previous reports (36, 37).”
ResultEvaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
Hirsch, F. R., Varella-Garcia, M., Franklin, W. A., Veve, R., Chen, L., Helfrich, B., Zeng, C., Baron, A., & Bunn, P. A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600286 · Cited by 246
“…diagnostic modalities in 20 – 30% of human breast cancers and is associated with a poorer overall survival and resistance to hormone based therapy (Slamon et al, 1987, 1989; Berchuck et al, 1990; Liu et al, 1992; Press et al, 1994; Pauletti et al, 1996; Allred and Swanson, 2000; Jacobs et al,…”
BackgroundAmplification of the gli gene in childhood sarcomas.
Roberts, W. M., Douglass, E., Peiper, S., Houghton, P. J., & Look, A. T. (1989) · PubMed · Cited by 246
Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245
“cCR + cPR 42 (88) cCR 17 (36) cPR 25 (52) cSD 5 (10) cPD 1 (2) Multigene Profiling of Resistance to Trastuzumab”
BackgroundOka, Y., Elisseeva, O. A., Tsuboi, A., Ogawa, H., Tamaki, H., Li, H., Oji, Y., Kim, E. H., Soma, T., Asada, M., et al. (2000) · Immunogenetics · doi:10.1007/s002510050018 · Cited by 245
“The c-erbB-2/HER-2/neu oncogene is amplified and overexpressed in a variety of human malignancies including breast and ovarian cancer (Gusterson et al. 1992; Slamon et al. 1987).”
BackgroundButt, A. J., McNeil, C. M., Musgrove, E. A., & Sutherland, R. L. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00993 · Cited by 244
“Dysregulation of growth factor receptor signalling is a hallmark of malignant progression in the breast (Slamon et al. 1987), and is often associated with increased activation of MAPK and PI 3-kinase S48 www.endocrinology-journals.org pathways (Sivaraman et al. 1997, Coutts & Murphy 1998, Santen et…”
BackgroundGoldman, R., Ben Levy, R., Peles, E., & Yarden, Y. (1990) · Biochemistry · doi:10.1021/bi00502a002 · Cited by 244
Selection and characterization of HER2/neu-binding affibody ligands
Wikman, M., Steffen, A.-C., Gunneriusson, E., Максимилианович, Т. В., Adams, G. P., Carlsson, J., & Ståhl, S. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh053 · Cited by 246
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
The HER-2/neu Oncogene in Tumors of the Gastrointestinal Tract
Ross, J. S., & McKenna, B. J. (2001) · Cancer Investigation · doi:10.1081/cnv-100103852 · Cited by 243
“Techniques used to detect HER-2/neu abnormalities in clinical specimens have included gene-based assays such as Southern and slot blotting, polymerase chain reaction (PCR) methods, and in-situ hybridization featuring both fluorescent (fluorescence in situ hybridization [FISH]) and nonfluorescent techniques (4,5).”
BackgroundMethodCreighton, C. J., Hilger, A. M., Murthy, S., Rae, J. M., Chinnaiyan, A. M., & El-Ashry, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4363 · Cited by 243
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
SLAMON, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90188-5 · Cited by 243
Self-citationWay, T.-D., Kao, M.-C., & Lin, J.-K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305529200 · Cited by 243
c-Src, Receptor Tyrosine Kinases, and Human Cancer
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60774-5 · Cited by 243
Evaluating HER2 amplification and overexpression in breast cancer
Bartlett, J. M. S., Going, J. J., Mallon, E. A., Watters, A. D., Reeves, J. R., Stanton, P., Richmond, J., Donald, B., Ferrier, R., & Cooke, T. G. (2001) · The Journal of Pathology · doi:10.1002/path.971 · Cited by 242
“Diagnostic HER2 tests have not so far been systematically compared with quantitative data from unfixed tissue [1,7,12].”
BackgroundRichman, S. D., Southward, K., Chambers, P., Cross, D., Barrett, J., Hemmings, G., Taylor, M., Wood, H., Hutchins, G., Foster, J. M., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4679 · Cited by 241
Systems Biology and Genomics of Breast Cancer
Perou, C. M., & Borresen-Dale, A.-L. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003293 · Cited by 241
Validation of Analytic Methods for Biomarkers Used in Drug Development
Chau, C. H., Rixe, O., McLeod, H., & Figg, W. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4535 · Cited by 241
Targeting Akt in cancer for precision therapy
Hua, H., Zhang, H., Chen, J., Wang, J., Liu, J., & Jiang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01137-8 · Cited by 241
Mallini, P., Lennard, T., Kirby, J., & Meeson, A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.008 · Cited by 240
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.